Skip to content

Clinical trials

Observational Pathologic Complete Response trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pathologic Complete Response Phase: Observational Country / region: China Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20191
20205
20211
20221
20232
20243
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed5
Unknown status5
Recruiting4
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sixth Affiliated Hospital, Sun Yat-sen University5
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Chinese Academy of Medical Sciences1
Jiangxi Provincial Cancer Hospital1
Peking Union Medical College Hospital1
Peking University1
Peking University Cancer Hospital & Institute1
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1
Shanghai Pulmonary Hospital, Shanghai, China1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pathologic Complete Response15
Rectal Neoplasms4
Breast Neoplasms2
Carcinoma, Non-Small-Cell Lung1
Esophageal Neoplasms1
Esophageal Squamous Cell Carcinoma1
Head and Neck Neoplasms1
Lymphoma, T-Cell, Peripheral1
Nasopharyngeal Carcinoma1
Recurrence1

Trials

Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.